Bank of New York Mellon
FTH

Bank of New York Mellon’s Faeth Therapeutics FTH Stock Holding History

Bank of New York Mellon’s Portfolio FTH Stock Details FTH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-2,704
Closed -$126K – 4687
2022
Q1 		$126K Sell
2,704
-68
-2% -$5.41K ﹤0.01% 4355
2021
Q4 		$322K Buy
2,772
+419
+18% +$62.6K ﹤0.01% 4055
2021
Q3 		$495K Buy
2,353
+1,431
+155% +$261K ﹤0.01% 3815
2021
Q2 		$180K Buy
922
+219
+31% +$54.1K ﹤0.01% 4122
2021
Q1 		$205K Buy
+703
New +$235K ﹤0.01% 4051

Other funds holding FTH

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
NM
Newtyn Management New York $936M AUM 27.23% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
DFO
Duquesne Family Office New York $3.38B AUM 61.92% 1-Year Est. Return
E
Ergoteles New York $68.2M AUM 36.16% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Bank of New York Mellon's FTH Position: Q2 2022 in Review

Bank of New York Mellon sold out of Faeth Therapeutics (FTH) in Q2 2022, closing a stake of 2,704 shares — an estimated $126K sold.

Bank of New York Mellon first reported a position in FTH in Q1 2021 and held it in 5 quarters. The position peaked at $495K in Q3 2021. 39 funds tracked by Wall St. Rank hold FTH as of Q2 2022.

  • Bank of New York Mellon reported no remaining Faeth Therapeutics position as of Q2 2022 after selling out during the quarter.
  • Bank of New York Mellon sold 2,704 Faeth Therapeutics shares in Q2 2022, an estimated $126K.
  • Bank of New York Mellon first reported a position in Faeth Therapeutics in Q1 2021 and held it in 5 quarters.
  • Bank of New York Mellon's Faeth Therapeutics position peaked at $495K in Q3 2021.
  • 39 funds tracked by Wall St. Rank held Faeth Therapeutics as of Q2 2022.

Based on Bank of New York Mellon's 13F filing for Q2 2022, filed 15 Aug 2022.